Tests Pola-R2 treatment in older adults with newly diagnosed lymphoma
Tests Pola-R2 drugs in older adults newly diagnosed with diffuse large B cell lymphoma.
Plain-language title generated from the registry record
Registry title: Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yan Zhang, MD
- Trial code
- NCT06176729
- Record updated
- 20 December 2023
- Original description
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).Read full original descriptionShow less
A Prospective Phase II Study of Polatuzumab, Rituximab, and Lenalidomide(Pola-R2) in Newly-diagnosed Non-fit Elderly DLBCL Patients
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).
Inclusion: The patient volunteered to participate in the study and signed the Informed Consent; Histopathologically confirmed DLBCL and treatment naive(corticosteroids alone is not considered as a line of treatment); Age≥ 70 years old, and was un-fit or frail according to comprehensive geriatric assessment; Adequate organ function and adequate bone marrow reserve.
Exclusion: Coexisting malignancy other than lymphoma; Active HBV infection; Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy.